Varian gains more worldwide sites for RapidArc system

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jose Sandoval Sus, MD, discussed the “revolution” that CAR T-cell therapies have facilitated for patients with large B-cell lymphomas.

Jacob Sands, MD

August 4th 2025

Cross-Collaboration is Key for Cellular Therapies Options Across Cancer Types

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Cellular therapies are a treatment modality that hold promise in various cancer types.

Navigating Second-Line Treatment Options in Urothelial Carcinoma

The 2025 National ICE-T Symposium gave oncology experts an opportunity to share ideas regarding the administration of cellular therapies.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

July 31st 2025

SC Epcoritamab Combo Met ORR/PFS End Points in R/R Follicular Lymphoma

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

$Pre-planned interim results from the phase EPCORE FL-1 trial supported the FDA granting priority review to epcoritamab with rituximab and lenalidomide in relapsed/refractory FL.$

Leading the Charge in Pediatric Oncology as the New ASPHO President

Pre-planned interim results from the phase EPCORE FL-1 trial supported the FDA granting priority review to epcoritamab with rituximab and lenalidomide in relapsed/refractory FL.

Ariana Pelosci

Considerations for CAR T Use Across Large B-Cell Lymphoma Variants

Balancing a career as a pediatric oncologist with leadership responsibilities, Maria C. Velez, MD, shares insights into her passion for the field and ASPHO’s impactful work.

Related Content

Roman Fabbricatore

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jose Sandoval Sus, MD, discussed the “revolution” that CAR T-cell therapies have facilitated for patients with large B-cell lymphomas.

Jacob Sands, MD

August 4th 2025

Cross-Collaboration is Key for Cellular Therapies Options Across Cancer Types

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Navigating Second-Line Treatment Options in Urothelial Carcinoma

The 2025 National ICE-T Symposium gave oncology experts an opportunity to share ideas regarding the administration of cellular therapies.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

July 31st 2025

SC Epcoritamab Combo Met ORR/PFS End Points in R/R Follicular Lymphoma

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

$Pre-planned interim results from the phase EPCORE FL-1 trial supported the FDA granting priority review to epcoritamab with rituximab and lenalidomide in relapsed/refractory FL.$

Leading the Charge in Pediatric Oncology as the New ASPHO President

Pre-planned interim results from the phase EPCORE FL-1 trial supported the FDA granting priority review to epcoritamab with rituximab and lenalidomide in relapsed/refractory FL.

Ariana Pelosci